18F-FDG PET/CT in preoperative staging of vulvar cancer patients: is it really effective?
- PMID: 28930828
- PMCID: PMC5617695
- DOI: 10.1097/MD.0000000000007943
18F-FDG PET/CT in preoperative staging of vulvar cancer patients: is it really effective?
Abstract
The aim of this study was to assess the role of 18F-FDG PET/CT in preoperative staging of vulvar cancer patients.29 pts (69 years, range 51-88) with vulvar cancer (clinical apparent stage I-II), underwent preoperative FDG-PET/CT scan followed by radical vulvectomy and bilateral (or monolateral in case of tumor >2 cm from midline) inguinal lymphadenectomy ± sentinel node biopsy. PET/CT images were analyzed in consensus and correlated to histological findings according to a pt-based and a groin-based analyses. SUVmax of the nodal uptake of each inguinal area (if present) was calculated and correlated to histological findings. The presence of distant metastases was also considered and confirmed.PET/CT analysis in consensus resulted negative at the inguinal LN level in 17 pts (10 true negative, 7 false negative) and positive in 12 pts (7 true positive, 5 false positive). Incidence of LN metastases resulted 48%. On pt-based analysis, sensitivity, specificity, accuracy, and negative and positive predictive value of PET/CT in detecting LN metastases were 50%, 67%, 59%, 59%, and 58%, respectively. On a groin-based analysis, considering overall 50 LN-sites, sensitivity, specificity, accuracy, and negative and positive predictive value of PET/CT were 53%, 85%, 73%, 67%, and 76%, respectively. The mean value of SUVmax was 6.1 (range 0.7-16.2) for metastatic nodes, whereas 1.6 (range 0.7 - 5.4) for negative lymph-nodes (P = .007). PET/CT detected pelvic (n = 1) and both pelvic/paraortic (n = 1) nodal metastases.In clinical early stage vulvar cancer FDG PET/CT showed low sensitivity and moderate specificity for N-staging; therefore, it is not an accurate tool for the nodal status assessment. PET/CT may not be cost-effective in detecting the rare event of distant metastases, but further studies are needed.
Conflict of interest statement
The authors have no funding and conflicts of interest to disclose.
Figures


Similar articles
-
Evaluation of Dual-Timepoint 18F-FDG PET/CT Imaging for Lymph Node Staging in Vulvar Cancer.J Nucl Med. 2017 Dec;58(12):1913-1918. doi: 10.2967/jnumed.117.194332. Epub 2017 May 25. J Nucl Med. 2017. PMID: 28546331
-
Identification of groin node metastasis in squamous cell vulval cancer using preoperative [18F] FDG-PET/CT. Can unnecessary lymphadenectomy be prevented?Eur J Obstet Gynecol Reprod Biol. 2025 Jun;310:113959. doi: 10.1016/j.ejogrb.2025.113959. Epub 2025 Apr 6. Eur J Obstet Gynecol Reprod Biol. 2025. PMID: 40209492
-
Whole-body [18F]fluoro-2-deoxyglucose positron emission tomography scan as combined PET-CT staging prior to planned radical vulvectomy and inguinofemoral lymphadenectomy for squamous vulvar cancer: a correlation with groin node metastasis.Eur J Gynaecol Oncol. 2014;35(3):230-5. Eur J Gynaecol Oncol. 2014. PMID: 24984533
-
18F-FDG PET and 18F-FDG PET/CT in Vulvar Cancer: A Systematic Review and Meta-analysis.Clin Nucl Med. 2021 Feb 1;46(2):125-132. doi: 10.1097/RLU.0000000000003411. Clin Nucl Med. 2021. PMID: 33234921
-
Diagnostic accuracy of preoperative 18F-FDG PET or PET/CT in detecting pelvic and para-aortic lymph node metastasis in patients with endometrial cancer: a systematic review and meta-analysis.Arch Gynecol Obstet. 2019 Sep;300(3):519-529. doi: 10.1007/s00404-019-05207-8. Epub 2019 Jun 4. Arch Gynecol Obstet. 2019. PMID: 31165242
Cited by
-
Imaging in Vulval Cancer.Cancers (Basel). 2024 Jun 19;16(12):2269. doi: 10.3390/cancers16122269. Cancers (Basel). 2024. PMID: 38927973 Free PMC article. Review.
-
A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies.Cancers (Basel). 2022 Mar 31;14(7):1779. doi: 10.3390/cancers14071779. Cancers (Basel). 2022. PMID: 35406552 Free PMC article. Review.
-
18F-FDG PET/MRI and 18F-FDG PET/CT for the Management of Gynecological Malignancies: A Comprehensive Review of the Literature.J Imaging. 2023 Oct 13;9(10):223. doi: 10.3390/jimaging9100223. J Imaging. 2023. PMID: 37888330 Free PMC article. Review.
-
European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023.Int J Gynecol Cancer. 2023 Jul 3;33(7):1023-1043. doi: 10.1136/ijgc-2023-004486. Int J Gynecol Cancer. 2023. PMID: 37369376 Free PMC article.
-
State of the art in vulvar cancer imaging.Radiol Bras. 2019 Sep-Oct;52(5):316-324. doi: 10.1590/0100-3984.2018.0072. Radiol Bras. 2019. PMID: 31656350 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30. - PubMed
-
- Koh WJ, Greer BE, Abu-Rustum NR, et al. Vulvar cancer, version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:92–120. - PubMed
-
- Guidelines for the Diagnosis and Management of Vulval Carcinoma. 2014. Available at: https://www.rcog.org.uk/globalassets/documents/guidelines/vulvalcancergu....
-
- Hacker NF, Eifel PJ, van der Velden J. Cancer of the vulva. Int J Gynaecol Obstet 2015;131(suppl 2):S76–83. - PubMed
-
- Zweizig S, Korets S, Cain JM. Key concepts in management of vulvar cancer. Best Pract Res Clin Obstet Gynaecol 2014;28:959–66. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical